Isracann Biosciences Inc. · OTC:ISCNF
Isracann Biosciences — Investor Presentation (January 2021)
15 slides from Isracann Biosciences's investor presentation, January 2021
Slide 1: Israel's First Pure-Play Cannabis Firm
CSE: IPOT Israel’s First Pure- Play Cannabis Firm Corporate Presentation
Slide 2: Legal
Legal Information contained in this presentation is the property of Isracann Biosciences Inc. (Isracann or the “Company”). This presentation does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in
Slide 3: About Isracann
About IIIIIIIIIIIII C I Israel’s First Pure-Play Cannabis Firm Isracann, Israel’s first pure-play cannabis firm, is focused on becoming a premier, low-cost cannabis producer. Isracann has a joint venture agreement in place with a built 55,000 sq ft farm, which is expandable to 160,000 sq ft in the n
Slide 4: The Opportunity in Israel
The Opportunity in Israel Optimal climatic conditions to grow medical cannabis Ideal Optimal Approx. 300 days High Humidity Temperature of Sun per Year UV rays Safeguarding the plant Reduces energy in winter and Optimal sun exposure Vital for effective growth from insects and enabling summer, saving
Slide 5: Israeli Market
Israeli Market Optimal climate for growing conditions will allow Isracann to be a low-cost producer serving the domestic market Haifa 10,000 patients on waitlist for medical cannabis due to supply constraints Number of medical cannabis patients doubles in under 2 years (topping 70,000) despite persi
Slide 6: Israel's Regulatory Overview
Israel’s Regulatory Overview Israeli government granted export approvals in Q2, 2020 • In 2007 Israel became the first country to allow medical research and cannabis cultivation. • Now its the 3rd country in the world to allow exports. • Cannabis is legal for medical purposes in Israel & decriminali
Slide 7: European Market
European Market Israel approved framework for exports of medical cannabis in January 2019 which positions it as the third country behind Canada and Netherlands able to export medical cannabis. Medical cannabis already available in 10 European countries. Europe population over 740 million, double USA
Slide 8: Business Model: Factors For Success
Business Model: Factors For Success Agricultural and Manufacturing Excellence Drive Industrial Scale Capability Cultivation Manufacturing o ISL/EU GMP Manufacturing Processes o Architectural design reviewed by Security consultant and Best Practices consultant. o Strategic LOI with Israeli manufactur
Slide 9: Business Model: Factors For Success
Business Model: Factors For Success Distribution to Major Markets Leverages Israeli Climatic, Cultural and Creative Excellence Distribution Branding o Israel’s massive domestic undersupply drives regional o Israel is recognized worldwide as a center for demand. excellence in agronomy, research, gene
Slide 10: The Facility
The Facility Isracann has a joint venture agreement in place with a built 55,000 sq. ft. farm, which is expandable to 160,000 sq. ft. in the near term and has access to over 2,000,000 sq. ft. of private land. Low-cost producer of high-grade medical marijuana, with anticipated cost of $0.40 per gram
Slide 11: Timeline
TIMELINE Preliminary Nursery Architectural Design Complete andCultivation ArchitecturalDesign Licenses Issued STEP2 Started STEP4 and Submitted To Israeli Land Authority for Approval STEP6 ISRACANN T I M E L INE START Israel Passes Export Security and EuropeanDistribution STEP1 Regulations STEP3 IMC
Slide 12: The Team
The Team Darryl Jones, President & CEO Mr. Jones has over 15 years of capital market experience and an established financial network. Prior to joining Isracann in 2018, Mr. Jones was an Investment Nitin Kaushal, Strategic Advisor advisor with PI Financial Corp Canada and Raymond James Ltd Canada. He
Slide 13: The Team
The Team Sean Bromley, Director Irit Arbel, Ph.D, Director Mr. Bromley works in corporate finance at a boutique merchant bank. A former investment advisor with experience working with public Dr. Arbel serves as CEO, Co-Founder and Director of Neurocords Ltd., a companies, he is currently a director
Slide 14: Sector Comparables
Sector Comparables Capitalization Valuation Statistics FY 2021 FY 2021 Share Enterprise Enterprise Value / EV ($MM) / Company Name Ticker Price Value ($CAD) Revenue ($MM) EBITDA ($MM) Revenue ($MM) EBITDA ($MM) IMC Cannabis IMCC $2.60 403 44.0 12.0 9.2 x 33.6 x Intercure Ltd INCR.TA $378.31 174 22.5
Slide 15: Thank You
Thank You Isracann Biosciences Inc. 1600-595 Burrard Street Vancouver, BC V7X 1L3 Canada Invictus Investor Relations +Toll Free: +1 855.205.0226 Email: [email protected] CSE: IPOT www.isracann.com
Isracann Biosciences — Investor Presentation (January 2021) on 6ix